Conferences - Results from #560

Viewing 561-580 of 11745 articles

AUA 2024: Phase I Study of Intravesical Fc-Optimized Anti-CD40 Agonist Antibody 2141-V11 for Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

AUA 2024: Midlife Baseline PSA as a Predictor of Lethal Prostate Cancer: Racial Differences between Black and White Men

AUA 2024: Paradigm-Shifting Clinical Trials in Urology: SWOG S1011 - Subgroup Analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for MIBC

AUA 2024: Exploring the Dual Impact to Treatment Outcomes in Patients with Short Time to Nadir PSA Under Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer

AUA 2024: Development of a Novel Risk Stratification for Prostate Cancer Patients Candidate to Radical Prostatectomy Staged with Preoperative PSMA-PET: The Key Role of Molecular Imaging

AUA 2024: Predicting Positive 68Ga-PSMA PET/CT Scans in Biochemical Recurrence Following Prostatectomy.

AUA 2024: Comparison of 68-Ga-PSMA PET/CT and Multiparametric MRI in Detecting Lymph Node Metastases in Patients with Intermediate or High-Risk Prostate Cancer

AUA 2024: Combination Regimen of Intravesical Docetaxel, Gemcitabine, and Cisplatin in Patients with BCG-unresponsive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

AUA 2024: Integrating MR and Ultrasound Images for AI-based Prostate Cancer Detection in Transrectal Ultrasound Images: A Comparative Assessment with Clinicians

AUA 2024: Characteristics of PI-RADS 5 Lesions with a Negative or Gleason Grade Group 1 Biopsy

AUA 2024: Enhancing Bone Health Screening for Prostate Cancer Patients Starting Androgen Deprivation Therapy: The Auto-Recruit Outpatient System

AUA 2024: Identifying The Optimal Candidate for Concomitant Androgen-Deprivation Therapy Among Patients Receiving Metastasis-Directed Therapy For Positive PSMA PET and Primary or Secondary Biochemical Recurrence from Prostate Cancer

AUA 2024: Correlation of Intraprostatic SUVmax During PSMA PET/CT and Adverse Pathology at Radical Prostatectomy

AUA 2024: Clinical Characterization of Metastatic Hormone Sensitive Prostate Cancer According to Real World Data: Can Randomized Clinical Trials Be More Reliable? Data from the European Network of Excellence for Big Data in Prostate Cancer (PIONEER)

AUA 2024: The Added Value of Concomitant Whole-Pelvis Salvage Radiation Therapy in Oligo-Recurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy for Distant Positive Uptakes at PSMA PET

AUA 2024: Development of a Prediction Model of Survival Amongst Patients with Metastatic Hormone Sensitive Prostate Cancer Using Big Data: Interim Results from the European Network of Excellence for Big Data in Prostate Cancer (PIONEER)

AUA 2024: A Multi-Center Randomized Controlled Trial Of Ambulatory Versus Inpatient Percutaneous Nephrolithotomy

AUA 2024: Outcomes for Localized Renal Cell Carcinoma Patients on Immunosuppression Following Organ Transplantation

AUA 2024: Does Deep Learning Reconstruction Improve Ureteral Stone Detection and Subjective Image Quality in the CT Images of Patients with Metal Hardware?

AUA 2024: The Role of PSA Doubling Time in the Stratification of Patients with a Negative PSMA PET After Biochemical Recurrence of Prostate Cancer: Implications for Tailored Salvage Treatment Strategies

24
25
26
27
28
29
30
31
32
33